<DOC>
	<DOCNO>NCT00002926</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness peripheral stem cell transplantation high-dose cytarabine treat patient myelodysplastic syndrome acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Peripheral Stem Cell Transplantation Treating Patients With Myelodysplastic Syndrome Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Assess value autologous peripheral stem cell transplantation versus high dose cytarabine ( Ara-C ) perform common induction consolidation course patient poor prognosis myelodysplastic syndrome ( MDS ) acute myelogenous leukemia secondary MDS . - Compare disease free survival overall survival patient reach complete recovery accord presence HLA-identical donor . - Monitor cytogenetic clonal remission intensive antileukemic therapy include stem cell transplantation . - Monitor residual disease hematopoietic clonal status autologous peripheral blood stem cell mobilize one consolidation course . - Assess recovery time granulocyte platelet count follow treatment step . OUTLINE : Induction treatment idarubicin day 1,3,5 ; Ara-C day 1 10 ; etoposide day 1 5 . On day 28 assessment response . If least partial response , cycle repeat induction course another 28 day . There peripheral blood stem cell collection cryopreservation follow family HLA-typing . If HLA match , remain remission consolidation course randomize either peripheral blood stem cell transplantation HiDAC treatment . PROJECTED ACCRUAL : 80 patient enter per year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathological confirmation one following : Untreated refractory anemia excess blast ( RAEB ) transformation RAEB great 10 % blast cell bone marrow Other myelodysplastic syndrome Profound cytopenias Acute myelogenous leukemia ( AML ) supervene overt myelodysplastic syndrome ( MDS ) 6 month duration No blast crisis chronic myeloid leukemia No leukemia supervene myeloproliferative disease No leukemia supervene overt MDS le 6 month duration The following allowed : Secondary acute leukemia follow Hodgkin 's disease malignancy Secondary leukemias follow exposure alkylating agent radiation PATIENT CHARACTERISTICS : Age : 1660 Performance status : WHO 02 Hematopoietic : If RAEB , blast cell great 10 % bone marrow Neutrophil count le 5,000 Platelet count le 200,000 Chronic myelomonocytic leukemia ( CMML ) great 5 % blast cell bone marrow , CMML neutrophil count great 160,000 monocyte count great 2,600 Hepatic : Bilirubin great 1.5 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : No patient severe heart failure require diuretic ejection fraction le 50 % Neurological : No severe concomitant neurological disease PRIOR CONCURRENT THERAPY : Biologic therapy : No treatment within past 4 week : Biological response modifier AND/OR Low dose AraC Chemotherapy : No prior intensive treatment MDS AML Endocrine therapy : Not specify Radiotherapy : No prior treatment MDS AML Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>